Loading...
Docoh

Acelrx Pharmaceuticals (ACRX)

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.

ACRX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
19 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 20.17M 20.17M 20.17M 20.17M 20.17M 20.17M
Cash burn (monthly) 552.33K 513.5K (no burn) (no burn) 2.92M 2.47M
Cash used (since last report) 916.29K 851.87K n/a n/a 4.84M 4.1M
Cash remaining 19.25M 19.31M n/a n/a 15.33M 16.07M
Runway (months of cash) 34.8 37.6 n/a n/a 5.3 6.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 22 Wan Mark A Common Stock Grant Acquire A No No 0 15,500 0 36,750
15 Jul 22 Wan Mark A Stock Option Common Stock Grant Acquire A No No 0.2309 31,000 7.16K 31,000
15 Jul 22 Rosen Howard B Common Stock Grant Acquire A No No 0 15,500 0 94,250
15 Jul 22 Rosen Howard B Stock Option Common Stock Grant Acquire A No No 0.2309 31,000 7.16K 31,000
15 Jul 22 Hoffman Stephen J Common Stock Grant Acquire A No No 0 15,500 0 36,750
15 Jul 22 Hoffman Stephen J Stock Option Common Stock Grant Acquire A No No 0.2309 31,000 7.16K 31,000
15 Jul 22 Adams Adrian Common Stock Grant Acquire A No No 0 15,500 0 211,750
15 Jul 22 Adams Adrian Stock Option Common Stock Grant Acquire A No No 0.2309 31,000 7.16K 31,000
15 Jul 22 Afable Richard Common Stock Grant Acquire A No No 0 15,500 0 37,750
15 Jul 22 Afable Richard Stock Option Common Stock Grant Acquire A No No 0.2309 31,000 7.16K 31,000
16.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 56 61 -8.2%
Opened positions 7 14 -50.0%
Closed positions 12 12
Increased positions 10 13 -23.1%
Reduced positions 14 11 +27.3%
13F shares Current Prev Q Change
Total value 17.29M 32.43M -46.7%
Total shares 23.92M 34.12M -29.9%
Total puts 11K 24.4K -54.9%
Total calls 38.3K 117.1K -67.3%
Total put/call ratio 0.3 0.2 +37.8%
Largest owners Shares Value Change
Rock Springs Capital Management 6.33M $1.81M +0.1%
BML Investment Partners 4.06M $7.64M 0.0%
D. E. Shaw & Co. 3.81M $1.09M +2.3%
Vanguard 3.47M $990K -31.9%
BLK Blackrock 2.22M $633K -0.3%
Geode Capital Management 1.07M $304K +8.9%
Values First Advisors 642.52K $183K +23.7%
STT State Street 448.73K $128K +3.2%
Bridgeway Capital Management 303.3K $87K 0.0%
NTRS Northern Trust 219.26K $62K 0.0%
Largest transactions Shares Bought/sold Change
Armistice Capital 0 -8.37M EXIT
Vanguard 3.47M -1.63M -31.9%
Millennium Management 85.21K -249.04K -74.5%
Citadel Advisors 92.46K -154.52K -62.6%
Values First Advisors 642.52K +123.24K +23.7%
Geode Capital Management 1.07M +87.51K +8.9%
D. E. Shaw & Co. 3.81M +87.41K +2.3%
Texas Capital Bank Wealth Management Services 80K +80K NEW
GS Goldman Sachs 0 -72.38K EXIT
UBS UBS Group AG - Registered Shares 400 -71.35K -99.4%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: alleviate, deposit, deteriorating, developmental, discharge, domestic, doubt, extinguishment, headcount, household, instrument, Lincoln, loosening, Park, prejudice, Premarket, ratably, Russia, Russian, salesforce, shift, subscription, sudden, Ukraine
Removed: abandon, affix, allocation, Anesthetic, ARPI, assignee, assisted, assumption, attributed, binding, brand, Brexit, British, BSI, calculate, calendar, cartridge, CE, charged, conclusion, concrete, conditionally, Conformit, confusional, considerably, controller, Cosmetic, CRL, deficiency, demonstrating, denial, depending, depression, description, deterrence, disagree, dispenser, dispute, disputed, distension, draft, EEA, embedded, enroll, error, finalization, forced, forecast, formatted, framework, functionality, halt, incidence, inconclusive, indemnifiable, inline, input, Institution, Interactive, interrupt, investigator, licensee, Linkbase, meaningful, misbranding, misplaced, mitigate, multicenter, NB, negotiated, observed, opportunity, originally, orthopedic, owing, oxycodegol, oxygen, Page, paradigm, performed, permit, pilot, postponed, postponement, preclinical, prescribe, prescribed, proactively, reached, realization, recommended, regulated, relaxed, remediate, remitted, repaid, reprocessing, resistance, resubmission, resubmitting, reviewing, revised, revolving, satisfaction, saturation, Schema, segment, selected, shelter, show, software, specific, sponsor, stakeholder, Steering, suffered, tachycardia, tailored, taxonomy, tightened, timeline, tongue, transdermal, unacceptable, undergone, underwent, underwriter, underwritten, upgraded, usability, version, worsening, XBRL

Reddit threads